Request Expert

Dr. received her M.D. degree from the University of Utah School of Medicine in 1988. She then completed training to practice in remote rural communities through a program at the McKay Dee Hospital for three years as a board certified Family Practice physician. She is currently board certified in Family Practice. She also has two industry certifications. In 2004, she was certified by the National Institute of Health, in clinical research training. The issues addressed in the training included ethical issues in human subject research, roles and responsibilities of the institution and investigator, regulatory rules and how to efficiently work with other clinical investigators and how to present information to the mass media. She was also certified by the WIRB in 2005, allowing her to review IRB proposals, perform site evaluation, recruiting and retention for various clinical investigations.

She is seasoned, highly versatile in clinical research, medical affairs and drug safety. She is a board certified MD and is currently active with a US medical license. She also has over 17 years industry experience. She has clinical and safety expertise in dermatology, hematology, ophthalmology, rheumatology, infectious disease, neurology, pulmonology, oncology and cardiology. She has experience in the senior level management and all Phases of clinical development I-IV clinical trial oversight, with leadership over medical affairs, clinical development, and clinical research and operations. She is familiar with pharmacovigilance, drug safety and business development review. She is able to work in fast-paced environments and conditions, is strategic, and a great team player and team builder.

She currently practices as an on-call rural Emergency Room Physician in the state of MN and has been for the past 5 years. However, her experience as a medical physician extends back to 1988, almost 21 years. Her experiences include being a physician in various divisions including blood bank, occupational medicine, urgent care and emergency room care at six different hospitals.

Dr. was a shareholder of a private family medicine clinic. She divided her time by committing to extensive sub-specialty clinical trials in multiple therapeutic areas as a principal investigator. She has in-depth experience with pain, asthma, infectious disease, cardiology and pulmonology trials. Overall, she served as a principal investigator or sub-investigator for over 40 trials in over 8 medical indications. Her other duties included clinical practice in all aspects of Family Medicine (including OB) and urgent care, treating close to 100 patients per day. She also participated actively in supervising a 24-physician group and organized weekly practice management and Quality Assurance meetings for the clinic.

Her leadership experiences also include serving as a director of a physician service group for two years. She was a physician liaison, working closely with a medical staff and the CEO to plan and organize meetings and events as well as to develop new policies. She was also a physician liaison to the administration for new physicians and MD group. She was also a monthly guest presenter for the Board and a liaison assistance and troubleshooter for the medical staff for a local hospital. Other administrative duties included developing a five-year plan for the clinic, analyzing the development of the medical staff based on the five-year plan. She performed community assessment analysis based on physicians’ needs, recruiting and developed a succession plan for physicians. She also oversaw the startup loans and contracts of the private practice. She also handled budget planning, submission, and review for her department.


Dr. has experience working as a medical and research director at an ophthalmology clinical research center in California for five years. Her duties included coordinating protocols and data management for multi-center clinical trials in several therapeutic areas including ocular allergic conditions, ocular hypertension, glaucoma, macular disease and ocular infections. She also supervised and consulted on drug safety and AE/SAE management.

Dr. served as a Medical Monitor for novel compounds in the treatment of Oncology clinical development including development of the protocol, CRFs and drug safety plan. She evaluated and analyzed the pharmaceutical aspect of various drugs used in oncology, including the inhibitors and suppression characteristics. She performed Drug Safety reviews and summaries. She provided narratives for FDA approval of various new drugs. She also reported on EMEA events. Additionally, she oversaw the clinical trial line listing data review and data base development with clinical trial oversight for enrollment, waivers, deviations and AE/SAE management.

Expert currently works for a global drug safety company providing drug safety in the areas of DMARDS, psoriasis, calcimimetics, osteoporosis and chemotherapy agents for a wide range of malignancies. Additionally, she assesses drug safety on chemotherapy adjuvant drugs, as well as in hematology drugs such as WBC (G-CSF), EPO (ESA), and Platelet colony stimulators. She performed drug safety on a large variety of both post marketed drugs and drug compounds under clinical trial (protocol) review using a particular system. She also reviewed SMOC cases. Other duties included assessing drug safety with pregnancy related cases. She was involved in the Standard Query Project for standardizing the evaluation and reviewing the process of 75 of the most common adverse events.

She was performed secondary review of G-CSF, hematology drugs such as Neulasta, Neupogen, N-Plate, Aranesp, with related propriety compounds under clinical trial development in the areas of anti inflammatory, oncology and G-CSF stimulation.

Expert has served as a medical monitor and clinical development consultant for a company that focused on dermatology related drugs for the past two years. She performed a multi center study on complicated skin and skin structure infections using a new antibiotic class of generation molecule. She also oversaw protocol development, monitoring and responding to all AE/SAEs, protocol deviation, waivers and enrollment. She ensured the approval of both the IRBs and the FDA for the various clinical studies performed by the company. She also organized and planned regular meetings with the company’s investigators to present protocol and drug safety.

She helped in the development of adverse medication lists for trial sites including Seizure threshold, QTc interval and immunosuppressive. She performed study reconciliation, line listing review and data review for the various studies and worked as the sponsor’s delegated Medical Monitor interface with sites, monitors, registered with FDA as medically responsible for various studies.


Dr. has been a consultant for a well-known pharmaceutical company consulting investigators on studies regarding complicated skin and skin structure infections as well as various other dermatologic conditions. She oversees the drug safety, acts as a Medical Officer and ensures all IRB requirements are met for each clinical study.